HPV VAX UPDATE
It appears that Merck is soon to have some competition.
GlaxoSmithKline is getting closer to launching its challenge against Merck’s monopoly on cervical cancer vaccines.
The British drugmaker GlaxoSmithKline (down $0.42 to $54.83, Charts) is just weeks away from filing an application for its experimental cervical cancer vaccine Cervarix to the Food and Drug Administration.
One Response to “HPV VAX UPDATE”
 Comment by Andrea March 15th, 2007 at 8:41 am |
YAY! Options are good. Cervical cancer is bad. |